Nivolumab - NCI - National Cancer Institute
Nivolumab works by binding to and blocking the protein PD-1 on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune …
Nivolumab: Uses, Dosage, Side Effects & Warnings - Drugs.com
Jun 15, 2025 · Nivolumab can cause serious, sometimes life-threatening, side effects in many different parts of your body. Some side effects may need to be treated with other medicines, …
Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors …
In the CheckMate 577 trial (17), nivolumab adjuvant therapy showed a significantly longer DFS than placebo in patients with resected esophageal or gastroesophageal junction cancer who …
What is the recommended use and dosage of Opdivo (nivolumab) in cancer ...
Oct 18, 2025 · Recommended Use and Dosage of Opdivo (Nivolumab) in Cancer Treatment Opdivo (nivolumab) is recommended as monotherapy at a dose of 240 mg every 2 weeks or …
FDA approves neoadjuvant/adjuvant nivolumab for resectable …
On October 3, 2024, the FDA approved neoadjuvant/adjuvant nivolumab with platinum-doublet chemotherapy for resectable non-small cell lung cancer.
Nivolumab Approved as Neoadjuvant, Adjuvant Therapy for …
Oct 4, 2024 · A study of neoadjuvant chemotherapy plus nivolumab versus neoadjuvant chemotherapy plus placebo, followed by surgical removal and adjuvant treatment with …
Nivolumab: Cancer Treatment Uses, Side Effects, Warnings
Nivolumab is a medication used in the treatment of many types of cancers (esophageal cancer, head and neck cancer, small cell and non-small cell [NSCLC] lung cancer, Hodgkin …
Adjuvant treatment of resected esophageal or gastroesophageal junction cancer 240 mg every 2 weeks or 480 mg every 4 weeks Until disease progression or unacceptable toxicity for a total …
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy …
Jun 2, 2025 · Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung …
Neoadjuvant Therapy in NSCLC: Nivolumab’s Curative Potential
Nov 3, 2025 · Dr Mark Kris continues the discussion on 5-year outcomes of neoadjuvant chemotherapy plus nivolumab in lung cancer, highlighting its curative potential and next steps.